These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 38282452)

  • 1. Impact of Antidiabetic Drugs on Clinical Outcomes of COVID-19: A Nationwide Population-Based Study.
    Jang HN; Moon SJ; Jung JH; Han KD; Rhee EJ; Lee WY
    Endocrinol Metab (Seoul); 2024 Jun; 39(3):479-488. PubMed ID: 38282452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study.
    Pérez-Belmonte LM; Torres-Peña JD; López-Carmona MD; Ayala-Gutiérrez MM; Fuentes-Jiménez F; Jorge Huerta L; Muñoz JA; Rubio-Rivas M; Madrazo M; Garcia MG; Montes BV; Sola JF; Ena J; Ferrer RG; Pérez CM; Ripper CJ; Lecumberri JJN; Acedo IEA; Canteli SP; Cosío SF; Martínez FA; Rodríguez BC; Pérez-Martínez P; Ramos-Rincón JM; Gómez-Huelgas R;
    BMC Med; 2020 Nov; 18(1):359. PubMed ID: 33190637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19.
    Rhee SY; Lee J; Nam H; Kyoung DS; Shin DW; Kim DJ
    Diabetes Metab J; 2021 Mar; 45(2):251-259. PubMed ID: 33752274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Can diabetes and its related hypoglycemic drug treatment be considered risk factors for health outcomes in COVID-19 patients? The results of a study in the population residing in Sicily Region (Southern Italy)].
    Cernigliaro A; Allotta AV; Scondotto S
    Epidemiol Prev; 2020; 44(5-6 Suppl 2):315-322. PubMed ID: 33412824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetes medications and associations with Covid-19 outcomes in the N3C database: A national retrospective cohort study.
    Bramante CT; Johnson SG; Garcia V; Evans MD; Harper J; Wilkins KJ; Huling JD; Mehta H; Alexander C; Tronieri J; Hong S; Kahkoska A; Alamgir J; Koraishy F; Hartman K; Yang K; Abrahamsen T; Stürmer T; Buse JB;
    PLoS One; 2022; 17(11):e0271574. PubMed ID: 36395143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-line glucose-lowering drugs added to metformin and the risk of hospitalization for heart failure: A nationwide cohort study.
    Lee SJ; Ha KH; Lee JH; Lee H; Kim DJ; Kim HC
    PLoS One; 2019; 14(2):e0211959. PubMed ID: 30742667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Association Between Antidiabetic Agents and Clinical Outcomes of COVID-19 Patients With Diabetes: A Bayesian Network Meta-Analysis.
    Chen Y; Lv X; Lin S; Arshad M; Dai M
    Front Endocrinol (Lausanne); 2022; 13():895458. PubMed ID: 35692410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
    Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
    Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dipeptidyl peptidase-4 (DPP-4) inhibitor and mortality in coronavirus disease 2019 (COVID-19) - A systematic review, meta-analysis, and meta-regression.
    Rakhmat II; Kusmala YY; Handayani DR; Juliastuti H; Nawangsih EN; Wibowo A; Lim MA; Pranata R
    Diabetes Metab Syndr; 2021; 15(3):777-782. PubMed ID: 33838614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin Use Is Associated With Reduced Mortality in a Diverse Population With COVID-19 and Diabetes.
    Crouse AB; Grimes T; Li P; Might M; Ovalle F; Shalev A
    Front Endocrinol (Lausanne); 2020; 11():600439. PubMed ID: 33519709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for COVID-19 case fatality rate in people with type 1 and type 2 diabetes mellitus: A nationwide retrospective cohort study of 235,248 patients in the Russian Federation.
    Shestakova MV; Vikulova OK; Elfimova AR; Deviatkin AA; Dedov II; Mokrysheva NG
    Front Endocrinol (Lausanne); 2022; 13():909874. PubMed ID: 36017317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of anti-diabetic drugs and covid-19 outcomes in patients with diabetes mellitus type 2 and chronic kidney disease: Nationwide registry analysis.
    Dimnjaković J; Buble T; Ivanko P; Poljičanin T; Karanović Štambuk S; Brborović H; Brborović O
    PLoS One; 2024; 19(3):e0301056. PubMed ID: 38536830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between glucose-lowering treatment and cancer metastasis among patients with preexisting type 2 diabetes and incident malignancy.
    Noh Y; Jeon SM; Shin S
    Int J Cancer; 2019 Apr; 144(7):1530-1539. PubMed ID: 30229901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiometabolic Therapy and Mortality in Very Old Patients With Diabetes Hospitalized due to COVID-19.
    Ramos-Rincón JM; Pérez-Belmonte LM; Carrasco-Sánchez FJ; Jansen-Chaparro S; De-Sousa-Baena M; Bueno-Fonseca J; Pérez-Aguilar M; Arévalo-Cañas C; Bacete Cebrian M; Méndez-Bailón M; Fiteni Mera I; González García A; Navarro Romero F; Tuñón de Almeida C; Muñiz Nicolás G; González Noya A; Hernández Milian A; García García GM; Alcalá Pedrajas JN; Herrero García V; Corral-Gudino L; Comas Casanova P; Meijide Míguez H; Casas-Rojo JM; Gómez-Huelgas R;
    J Gerontol A Biol Sci Med Sci; 2021 Jul; 76(8):e102-e109. PubMed ID: 33945610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Antidiabetic Therapy on Clinical Outcomes of COVID-19 Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis.
    Zhan K; Weng L; Qi L; Wang L; Lin H; Fang X; Jia H; Ma X
    Ann Pharmacother; 2023 Jul; 57(7):776-786. PubMed ID: 36314281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records.
    Zghebi SS; Steinke DT; Rutter MK; Emsley RA; Ashcroft DM
    Diabetes Obes Metab; 2016 Sep; 18(9):916-24. PubMed ID: 27177784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of antidiabetic agents on dementia risk: A Bayesian network meta-analysis.
    Zhou JB; Tang X; Han M; Yang J; Simó R
    Metabolism; 2020 Aug; 109():154265. PubMed ID: 32446679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin use and risk of COVID-19 among patients with type II diabetes mellitus: an NHIS-COVID-19 database cohort study.
    Oh TK; Song IA
    Acta Diabetol; 2021 Jun; 58(6):771-778. PubMed ID: 33582839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.